Filana Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Filana Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 89% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-210.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 89% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Filana Therapeutics, Inc. made a loss over the last year. Filana Therapeutics, Inc. owes $0.39 for every $1 it owns. Filana Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossFilana Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.50The share price is 0.50 times Filana Therapeutics, Inc.'s book value per share, lower than 91% of Healthcare companies in United States.
Market cap
$32 MThe total market value of all of Filana Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 79% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$64 MWhat Filana Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.32Net worth divided by the number of shares. The share price of $0.65 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
-55.8%Filana Therapeutics, Inc. lost 55.8% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
Owes vs Owns
0.39×Filana Therapeutics, Inc. owes $0.39 for every $1 it owns (low), lower than 52% of Healthcare companies in United States.
Dividend yield
NoneFilana Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossFilana Therapeutics, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Filana Therapeutics, Inc.: $32 M ÷ $64 M (30 Jun 2026) = 0.5.
What is Filana Therapeutics, Inc.'s return on equity?
Filana Therapeutics, Inc. lost 55.8% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
How much does Filana Therapeutics, Inc. owe compared with what it owns?
Filana Therapeutics, Inc. owes $0.39 for every $1 it owns (low), lower than 52% of Healthcare companies in United States.
Does Filana Therapeutics, Inc. pay a dividend?
No. Filana Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.